Conference Correspondent
Beth Faiman reviews the steps she takes upon introducing patients to daratumumab. Read More ›
Beth Faiman sees daratumumab as a game changer for patients with multiple myeloma. Read More ›
Beth Faiman reflects on the considerations involved with managing patients who have experienced multiple myeloma relapses. Read More ›
Treatment of elderly and/or unfit chronic lymphocytic leukemia (CLL) patients with chlorambucil plus rituximab was associated with low toxicity, a high overall response rate, and durable progression-free survival, suggesting that in low-risk unfit patients, this combination may be an optimal therapeutic option taking into consideration safety, efficacy, and cost. Read More ›
Healthcare utilization of elderly chronic lymphocytic leukemia (CLL) patients who remain on bendamustine-rituximab (BR) is significantly lower than patients who remain on fludarabine, cyclophosphamide, and rituximab (FCR), with FCR-treated patients experiencing significantly more days of hospitalization, outpatient visits, and emergency department visits than BR-treated patients. Read More ›
In an effort to determine whether lower peripheral neuropathy rates could be achieved, this study evaluated the efficacy and safety of subcutaneous bortezomib in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma. Read More ›
Using a novel electronic health record database that included nearly 800 chronic lymphocytic leukemia patients, recent treatment patterns in the United States showed a decline in the use of fludarabine-, bendamustine-, and rituximab-containing regimens and a significant increase in the use of obinutuzumab and ibrutinib, either as monotherapy or in combination regimens. Read More ›
Targeted therapy in the management of non–small-cell lung cancer is discussed. Read More ›
Prophylactic pegfilgrastim was associated with fewer neutropenic events in patients receiving a CHOP-based regimen in DLBCL. Read More ›
An analysis of the efficacy and cost-effectiveness of 3 colony-stimulating factors— filgrastim, tbo-filgrastim, and filgrastim-sndz—is presented. Read More ›